company background image
2880

Shenzhen Weiguang Biological Products SZSE:002880 Stock Report

Last Price

CN¥25.38

Market Cap

CN¥5.8b

7D

1.0%

1Y

-26.4%

Updated

08 Aug, 2022

Data

Company Financials
2880 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance4/6
Financial Health5/6
Dividends2/6

2880 Stock Overview

Shenzhen Weiguang Biological Products Co., Ltd.

Shenzhen Weiguang Biological Products Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Shenzhen Weiguang Biological Products
Historical stock prices
Current Share PriceCN¥25.38
52 Week HighCN¥37.00
52 Week LowCN¥21.50
Beta0.10
1 Month Change-2.01%
3 Month Change2.09%
1 Year Change-26.41%
3 Year Change20.91%
5 Year Change-7.40%
Change since IPO47.40%

Recent News & Updates

Shareholder Returns

2880CN BiotechsCN Market
7D1.0%0.4%-0.5%
1Y-26.4%-33.3%-10.4%

Return vs Industry: 002880 exceeded the CN Biotechs industry which returned -33.3% over the past year.

Return vs Market: 002880 underperformed the CN Market which returned -10.4% over the past year.

Price Volatility

Is 2880's price volatile compared to industry and market?
2880 volatility
2880 Average Weekly Movement3.4%
Biotechs Industry Average Movement5.6%
Market Average Movement6.1%
10% most volatile stocks in CN Market9.2%
10% least volatile stocks in CN Market3.9%

Stable Share Price: 002880 is less volatile than 75% of CN stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: 002880's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1985759Zhan Zhanghttps://www.szwg.com

Shenzhen Weiguang Biological Products Co., Ltd. primarily engages in the research, development, production, and sale of blood products in China. The company offers human albumin, intravenous immunoglobulin (pH4), freeze-dried intravenous human immunoglobulin (pH4), human immunoglobulin, hepatitis B human immunoglobulin, rabies patient immunoglobulin, tetanus human immunoglobulin, histamine human immunoglobulin, and human fibrinogen, as well as a total of 9 varieties and 21 specifications.

Shenzhen Weiguang Biological Products Co., Ltd. Fundamentals Summary

How do Shenzhen Weiguang Biological Products's earnings and revenue compare to its market cap?
2880 fundamental statistics
Market CapCN¥5.76b
Earnings (TTM)CN¥203.78m
Revenue (TTM)CN¥906.57m

28.2x

P/E Ratio

6.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
2880 income statement (TTM)
RevenueCN¥906.57m
Cost of RevenueCN¥533.09m
Gross ProfitCN¥373.48m
Other ExpensesCN¥169.70m
EarningsCN¥203.78m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.90
Gross Margin41.20%
Net Profit Margin22.48%
Debt/Equity Ratio10.2%

How did 2880 perform over the long term?

See historical performance and comparison

Dividends

0.8%

Current Dividend Yield

22%

Payout Ratio